The FDA will examine results of earlier studies of other vaccines made by AstraZeneca scientists to see if similar side effects emerged in those trials. The investigation doesn’t mean the FDA has safety concerns about any of the other vaccines it’s looking at, Business Insider reported.
The U.S. trial of AstraZeneca’s vaccine was halted Sept. 9. after a woman in the U.K. participating in the trial was diagnosed with transverse myelitis, a rare neurological condition in which the spinal cord becomes inflamed. The trial has resumed in the U.K., South Africa, India and Brazil.
European regulators are expected to announce a review of the vaccine as soon as this week, Business Insider reported.
AstraZeneca CEO Pascal Soriot said Sept. 10 that the company still expects to know by the end of the year if the vaccine is safe and effective.
More articles on pharmacy:
7 former FDA commissioners write opinion column lamenting White House’s treatment of agency
Celgene, Teva schemed to keep drug prices high, boost profits, US House panel finds
UnitedHealth acquires competitor to Amazon’s PillPack
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
